Vintage Victory: Warfarin Versus Apixaban in the Antiphospholipid Arena.

Sabina, Michael; Barakat, Zein; Costa Guerra, Bernardo; Lurie, Andrew; Khan, Zoya

Sabina, Michael; Barakat, Zein; Costa Guerra, Bernardo; Lurie, Andrew; Khan, Zoya.

Afiliación

Sabina M; Internal Medicine, Lakeland Regional Health Medical Center, Lakeland, USA.
Barakat Z; Internal Medicine, Lakeland Regional Health Medical Center, Lakeland, USA.
Costa Guerra B; Internal Medicine, Lakeland Regional Health Medical Center, Lakeland, USA.
Lurie A; Research, Nova Southeastern University Dr. Kiran C. Patel College of Osteopathic Medicine, Davie, USA.
Khan Z; Research, Lakeland Regional Health Medical Center, Lakeland, USA.

Cureus ; 16(3): e57040, 2024 Mar.

Article en En | MEDLINE | ID: mdl-38681463

ABSTRACT

ABSTRACT

This case report explores the efficacy of warfarin compared to apixaban in managing antiphospholipid syndrome (APS), an autoimmune disorder characterized by recurrent thrombosis. We emphasize the constraints of direct oral anticoagulants (DOACs) such as apixaban in APS management. This case discusses a 41-year-old female patient with APS who did not respond to apixaban therapy. The report details her transition to warfarin, resulting in symptom resolution and no further complications, thus alluding to warfarin's effectiveness in APS management over apixaban. The case contributes to the ongoing debate on the suitability of modern DOACs in APS treatment.

Palabras clave

antiphospholipid syndrome (aps); apixaban; direct oral anticoagulants (doacs); thrombosis management; warfarin

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cureus Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google